E-LIB Suche - Ergebnisse für: Schernthaner, G.

1

Factors influencing safe glucose-lowering in older adults w..:

Hambling, C.E. ; Khunti, K. ; Cos, X....
Primary Care Diabetes. 13 (2019) 4 - p. 330-352 , 2019

Link: https://doi.org/10.1016/..

2

Prevalence, glucose control and relative survival of people..:

Holden, S. E. ; Jenkins-Jones, S. ; Morgan, C. Ll....
Diabetic Medicine. 34 (2017) 6 - p. 770-780 , 2017

Link: https://doi.org/10.1111/..

3

Secular trends in antihyperglycaemic medication prescriptio..:

Clemens, K. K. ; Liu, K. ; Shariff, S....
Diabetes, Obesity and Metabolism. 18 (2016) 6 - p. 607-614 , 2016

Link: https://doi.org/10.1111/..

4

Glucose-lowering therapy in type 2 diabetes: New hope after..:

Schernthaner, G. ; Schernthaner, G.-H.
Herz. 41 (2016) 3 - p. 208-216 , 2016

Link: https://doi.org/10.1007/..

5

Treatment escalation options for patients with type 2 diabe..:

Schernthaner, G. ; Rosas‐Guzmán, J. ; Dotta, F....
Diabetes, Obesity and Metabolism. 17 (2015) 7 - p. 689-698 , 2015

Link: https://doi.org/10.1111/..

6

P319 Tolérance de la linagliptine chez 8 778 patients diabé..:

Schernthaner, G. ; Khunti, K. ; Patel, S....
Diabetes & Metabolism. 41 (2015) - p. A114 , 2015

Link: https://doi.org/10.1016/..

7

How attractive is the combination of a sodium glucose co‐tr..:

Schernthaner, G. ; Schernthaner‐Reiter, M. H.
Diabetes, Obesity and Metabolism. 17 (2015) 7 - p. 613-615 , 2015

Link: https://doi.org/10.1111/..

8

Efficacy and tolerability of saxagliptin compared with glim..:

Schernthaner, G. ; Durán‐Garcia, S. ; Hanefeld, M....
Diabetes, Obesity and Metabolism. 17 (2015) 7 - p. 630-638 , 2015

Link: https://doi.org/10.1111/..

9

Glucose-lowering with exogenous insulin monotherapy in type..:

Holden, S.E. ; Jenkins-Jones, S. ; Morgan, C.L...
Value in Health. 17 (2014) 3 - p. A240 , 2014

Link: https://doi.org/10.1016/..

10

Safety and efficacy of the dipeptidyl peptidase-4 inhibitor..:

Schernthaner, G. ; Barnett, A. H. ; Patel, S....
Diabetes, Obesity and Metabolism. 16 (2014) 11 - p. 1078-1086 , 2014

Link: https://doi.org/10.1111/..

11

Can people with type 2 diabetes live longer than those with..:

Bannister, C. A. ; Holden, S. E. ; Jenkins-Jones, S....
Diabetes, Obesity and Metabolism. 16 (2014) 11 - p. 1165-1173 , 2014

Link: https://doi.org/10.1111/..

12

Proceedings From an International Consensus Meeting on Post..:

Sharif, A. ; Hecking, M. ; de Vries, A.P.J....
American Journal of Transplantation. 14 (2014) 9 - p. 1992-2000 , 2014

Link: https://doi.org/10.1111/..

13

Glucose-lowering with exogenous insulin monotherapy in type..:

Holden, S. E. ; Jenkins-Jones, S. ; Morgan, C. Ll...
Diabetes, Obesity and Metabolism. 17 (2014) 4 - p. 350-362 , 2014

Link: https://doi.org/10.1111/..

14

P338 Comparaison entre la canagliflozine et la sitagliptine..:

Schernthaner, G. ; Gross, J. ; Fu, M....
Diabetes & Metabolism. 40 (2014) - p. A107 , 2014

Link: https://doi.org/10.1016/..

15

Safety and tolerability of linagliptin: a pooled analysis o..:

Schernthaner, G. ; Barnett, A. H. ; Emser, A....
Diabetes, Obesity and Metabolism. 14 (2012) 5 - p. 470-478 , 2012

Link: https://doi.org/10.1111/..